Neuroprotective effects of edaravone on dopaminergic neurons in Parkinson's disease
Author Information
Author(s): Ji Yuan Wen, Yasuhara Takao, Shingo Tetsuro, Muraoka Kenichiro, Agari Takashi, Kameda Masahiro, Uozumi Takashi, Tajiri Naoki, Morimoto Takamasa, Jing Meng, Baba Tanefumi, Wang Feifei, Leung Hanbai, Matsui Toshihiro, Miyoshi Yasuyuki, Date Isao
Primary Institution: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Hypothesis
Edaravone has neuroprotective effects on TH-positive dopaminergic neurons treated with 6-OHDA.
Conclusion
Edaravone exerts neuroprotective effects on a Parkinson's disease model both in vitro and in vivo.
Supporting Evidence
- Edaravone significantly improved the survival of TH-positive neurons in a dose-responsive manner.
- Edaravone reduced the number of apoptotic cells and HEt-positive cells.
- Behavioral tests showed that edaravone reduced amphetamine-induced rotations in rats.
- TH staining indicated that edaravone preserved dopaminergic fibers in the striatum.
Takeaway
Edaravone helps protect brain cells in a disease that affects movement, like Parkinson's, by reducing damage and helping cells survive.
Methodology
The study used in vitro and in vivo models to assess the effects of edaravone on dopaminergic neurons exposed to 6-OHDA.
Limitations
The high therapeutic dosage of edaravone for clinical application remains unresolved.
Participant Demographics
Adult female Sprague-Dawley rats weighing 250–300 g.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website